News
-
![Aspire Biopharma]()
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30…
-
![Aspire Biopharma]()
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it has received Institutional Review Board (IRB) approval of the clinical trial protocol…
-
![Aspire Biopharma]()
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, CEO of Aspire, will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: April 17, 2025Time of Presentation: 12:35 p.m. EDTFormat: Corporate presentation with…
-
![Aspire Biopharma]()
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
Highlights HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / April 11, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending disruptive drug and supplement delivery technology, announced today it has begun initial production of its single dose pre workout supplement utilizing Aspire’s patent-pending and proprietary sublingual delivery…
-
![Aspire Biopharma]()
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Highlights HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation. One clinical…
-
![Aspire Biopharma]()
Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA-Approved Drugs, Nutraceuticals and Supplements
Highlights Humacao, PR and New York, NY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (Nasdaq: PWUP), a Nasdaq Global Market® listed special purpose acquisition company, (“PowerUp”), have entered into a definitive agreement and plan of merger…
-
![Aspire Biopharma]()
Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.
HUMACAO, PR and NEW YORK, NY, July 31, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (Nasdaq: PWUP), a Nasdaq Global Market® listed special purpose acquisition company (“PowerUp”), today announced that they have signed a non-binding letter of intent (“LOI”) for a potential business…
-
![Aspire Biopharma]()
Aspire Biopharma, Inc. Engages CTM Advisory, Ltd., and Receives Advisory Engagement from Spartan Capital Securities, LLC to Explore NASDAQ Listed Company Merger
HUMACAO, PR, March 20, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the engagement of CTM Advisory, Ltd. and has received an advisory engagement and expects to engage Spartan Capital Securities, LLC to manage the merger transaction. CTM Advisory, has been engaged by Aspire, to use its expertise…
-
![Aspire Biopharma]()
Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.
HUMACAO, PR, January 18, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that it has organized and solidified its timeline for its contemplated 505(b) fast track FDA Trial on its initial sublingual aspirin product. Aspire will be meeting with Glatt Air Techniques, its development and production partner team,…
-
![]()
Aspire Biopharma, Inc. Announces Newly Appointed Medical Advisory Board Members
HUMACAO, PR, September 5, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of three new members to its Medical Advisory Board. Aspire Biopharma, Inc. is excited to announce the addition of three new highly qualified advisors to its Medical Advisory Board, including…
